Biodexa Pharmaceuticals annual gross profit
2015
2016
2017
2022
2023
2024
2025
Biodexa Pharmaceuticals Gross Profit Growth & History (BDRX)
Biodexa Pharmaceuticals's gross profit was −£4.0M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£4.0M | £1.5M | — |
| 2024 | 2024-12-31 | −£5.4M | −£1.8M | — |
| 2023 | 2023-12-31 | −£3.7M | £726,000 | — |
| 2022 | 2022-12-31 | −£4.4M | — | — |
| 2017 | 2017-12-31 | £6.7M | £416,000 | +6.65% |
| 2016 | 2016-12-31 | £6.3M | £5.0M | +379.39% |
| 2015 | 2015-12-31 | £1.3M | — | — |
Biodexa Pharmaceuticals gross profit trends
Between the periods ended 2015-12-31 and 2025-12-31, Biodexa Pharmaceuticals's gross profit decreased from £1.3M to −£4.0M, a change of −£5.3M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...